All data are based on the daily closing price as of March 20, 2026
h
Hisamitsu Pharmaceutical
4530.TSE
37.96 USD
-0.09
-0.24%
Overview
Last close
37.96 usd
Market cap
2.67B usd
52 week high
41.89 usd
52 week low
25.59 usd
Target price
27.16 usd
Valuation
P/E
15.6542
Forward P/E
12.2699
Price/Sales
2.656
Price/Book Value
1.5732
Enterprise Value
1.98B usd
EV/Revenue
2.0232
EV/EBITDA
9.6858
Key financials
Revenue TTM
976.59M usd
Gross Profit TTM
583.34M usd
EBITDA TTM
156.14M usd
Earnings per Share
1.69 usd
Dividend
0.55 usd
Total assets
2.19B usd
Net debt
-634.59M usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.